Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Molecular Response According to Type of Preexisting BCR-ABL Mutations after Second Line Dasatinib Therapy in Chronic Phase CML Patients.

Martin C. Mueller, MD, Philipp Erben, MD, Thomas Ernst, MD, Michelle Giehl, PhD, Thomas Schenk, MD, Jana Hoffmann, Stephanie Lauber, MD, Jens Kruth, MD, Benjamin Hanfstein, MD, Eric Bleickardt, MD, Claude Nicaise, MD, Rüdiger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2007) 110 (11): 319.

https://doi.org/10.1182/blood.V110.11.319.319

Published: 2007

Journal Articles

Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP).

Jorge Cortes, MD, Susan O’Brien, MD, Dan Jones, MD, Charles Koller, MD, Gautam Borthakur, MD, Claude Nicaise, MD, Laverne Henderson, RN, Alessandra Ferrajoli, MD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 30.

https://doi.org/10.1182/blood.V110.11.30.30

Published: 2007

Journal Articles

Dasatinib (Sprycel™) Therapy for Patients with Systemic Mastocytosis.

Srdan Verstovsek, MD, PhD, Hagop Kantarjian, M.D., Jorge Cortes, M.D., Farhad Ravandi-Kashani, M.D., Gautam Borthakur, M.D., Claude Nicaise, M.D., Inga Sams, M.D., Francis Giles, M.D., Ayalew Tefferi, M.D.

Blood (2006) 108 (11): 3627.

https://doi.org/10.1182/blood.V108.11.3627.3627

Published: 2006

Journal Articles

Response to Dasatinib after Imatinib Failure According to Type of Preexisting BCR-ABL Mutations.

Martin C. Müller, MD, Philipp Erben, MD, Thomas Schenk, MD, Stephanie Lauber, MD, Jens Kruth, MD, Jana Hoffmann, Thomas Ernst, MD, Tanja Lahaye, MD, Georgia Metzgeroth, MD, Michael Acevedo, PhD, Claude Nicaise, MD, Rudiger Hehlmann, MD, Andreas Hochhaus, MD

Blood (2006) 108 (11): 748.

https://doi.org/10.1182/blood.V108.11.748.748

Published: 2006

Journal Articles

Potent Transient Inhibition of BCR-ABL by Dasatinib Leads to Complete Cytogenetic Remissions in Patients with Chronic Myeloid Leukemia: Implications for Patient Management and Drug Development.

Neil P. Shah, MD, PhD, John M. Nicoll, BS, Eric Bleickardt, MD, Claude Nicaise, MD, Ronald L. Paquette, MD, Charles L. Sawyers, MD

Blood (2006) 108 (11): 2166.

https://doi.org/10.1182/blood.V108.11.2166.2166

Published: 2006

Journal Articles

Cytopenias in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib (SPRYCEL®): Clinical Features and Management, Including Outcome after Hematopoietic Growth Factor Therapy.

Alfonso Quintas-Cardama, MD, Hagop M. Kantarjian, MD, Claude Nicaise, MD, Guillermo Garcia-Manero, MD, Susan O’Brien, MD, Farhad Ravandi, MD, Stefan Faderl, MD

Blood (2006) 108 (11): 2163.

https://doi.org/10.1182/blood.V108.11.2163.2163

Published: 2006

Journal Articles

Pleural Effusion in Patients (pts) with Chronic Myelogenous Leukemia (CML) Treated with Dasatinib after Imatinib Failure.

Alfonso Quintas-Cardama, MD, Hagop M. Kantarjian, MD, Reginald Munden, MD, Moshe Talpaz, MD, John Bruzzi, MD, Susan O’Brien, MD, Guillermo Garcia-Manero, MD, Claude Nicaise, MD, Jorge Cortes, MD

Blood (2006) 108 (11): 2164.

https://doi.org/10.1182/blood.V108.11.2164.2164

Published: 2006

Journal Articles

Dasatinib (BMS-354825) is active in Philadelphia chromosome–positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure

Alfonso Quintas-Cardama, Hagop Kantarjian, Dan Jones, Claude Nicaise, Susan O'Brien, Francis Giles, Moshe Talpaz, Jorge Cortes

Blood (2006) 109 (2): 497–499.

https://doi.org/10.1182/blood-2006-07-035493

Published: 2006

Journal Articles

Correlation of Clinical Response to Dasatinib (BMS-354825) with BCR-ABL Mutation Status in Imatinib- Resistant Patients (pts) with Chronic Myeloid Leukemia (CML) Treated at MD Anderson Cancer Center (MDACC).

Elias Jabbour, MD, Jorge Cortes, MD, Moshe Talpaz, MD, Dan Jones, MD, PhD., Susan O’Brien, MD, Claude Nicaise, MD, Hagop Kantarjian, MD

Blood (2005) 106 (11): 1091.

https://doi.org/10.1182/blood.V106.11.1091.1091

Published: 2005

Journal Articles

Molecular Analysis of Dasatinib Resistance Mechanisms in CML Patients Identifies Novel BCR-ABL Mutations Predicted To Retain Sensitivity to Imatinib: Rationale for Combination Tyrosine Kinase Inhibitor Therapy.

Neil P. Shah, MD, PhD, John M. Nicoll, Susan Branford, Timothy P. Hughes, MD, Ronald L. Paquette, MD, Moshe Talpaz, MD, Claude Nicaise, MD, Fei Huang, Charles L. Sawyers, MD

Blood (2005) 106 (11): 1093.

https://doi.org/10.1182/blood.V106.11.1093.1093

Published: 2005

NARROW

Molecular Response According to Type of Preexisting BCR-ABL Mutations after Second Line Dasatinib Therapy in Chronic Phase CML Patients.

Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP).

Dasatinib (Sprycel™) Therapy for Patients with Systemic Mastocytosis.

Response to Dasatinib after Imatinib Failure According to Type of Preexisting BCR-ABL Mutations.

Potent Transient Inhibition of BCR-ABL by Dasatinib Leads to Complete Cytogenetic Remissions in Patients with Chronic Myeloid Leukemia: Implications for Patient Management and Drug Development.

Cytopenias in Patients (pts) with Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) Treated with Dasatinib (SPRYCEL®): Clinical Features and Management, Including Outcome after Hematopoietic Growth Factor Therapy.

Pleural Effusion in Patients (pts) with Chronic Myelogenous Leukemia (CML) Treated with Dasatinib after Imatinib Failure.

Dasatinib (BMS-354825) is active in Philadelphia chromosome–positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure

Correlation of Clinical Response to Dasatinib (BMS-354825) with BCR-ABL Mutation Status in Imatinib- Resistant Patients (pts) with Chronic Myeloid Leukemia (CML) Treated at MD Anderson Cancer Center (MDACC).

Molecular Analysis of Dasatinib Resistance Mechanisms in CML Patients Identifies Novel BCR-ABL Mutations Predicted To Retain Sensitivity to Imatinib: Rationale for Combination Tyrosine Kinase Inhibitor Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only